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Randomized controlled pilot trial of naloxone-on-release to prevent post-prison opioid overdose 
deaths 
 
ABSTRACT 
 
Background and aims: Naloxone is an opioid antagonist used for emergency resuscitation following 
opioid overdose.  Prisoners with a history of heroin injection have a high risk of drug-related death 
soon after release from prison.  The N-ALIVE pilot trial (ISRCTN34044390) tested feasibility measures 
for randomized provision of naloxone-on-release (NOR) to eligible prisoners in England. 
 
Design: Parallel group randomized controlled pilot trial.  
 
Setting: English prisons. 
 
Participants: A total of 1685 adult heroin injectors, incarcerated for at least 7 days pre-
randomization, release due within 3 months and more than 6 months since previous N-ALIVE 
release.  
 
Intervention: Using 1:1 minimization, prisoners were randomized to receive on-release a pack 
containing either a single ‘rescue’ injection of naloxone or a control pack with no syringe.  
 
Measurements: Key feasibility outcomes were tested against prior expectations: on participation (14 
English prisons; 2800 prisoners), consent (75% for randomization), returned prisoner self-
questionnaires (RPSQs: 207), NOR-carriage (75% in first 4-weeks) and overdose-presence (80%).  
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Findings: Prisons (16) and prisoners (1685) were willing to participate (consent-rate, 95% CI: 70% to 
74%); 218 RPSQs were received; NOR-carriage (95% CI: 63% to 79%) and overdose-presence (95% CI: 
75% to 84%) were as expected. We randomized 842 to NOR, 843 to control during 30 months but 
stopped early because only one third of NOR administrations was to the ex-prisoner.  Nine deaths 
within 12 weeks of release were registered for 1557 randomized participants released before 9 
December 2014. 
 
Conclusions: Large randomized trials are feasible with prison populations. Provision of take-home 
emergency naloxone prior to prison release may be a life-saving interim measures to prevent heroin 
overdose deaths among ex-prisoners and the wider population. 
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INTRODUCTION 
Prisoners with a history of heroin injection have a high risk of drug-related death (DRD) soon after 
prison-release which was estimated at 5 DRDs per 1000 eligible releases on the basis of record-
linkage studies in Scotland in 1996-991, and in England and Wales in 1999-2002.2  See also meta-
analyses3 4. 
 
Naloxone is an opioid antagonist that can be administered intramuscularly and is used by emergency 
services to reverse heroin/opioid overdose5. The feasibility of randomized provision of naloxone-on-
release (NOR) to a high-DRD-risk population, such as inmates with a history of heroin injection use 
on their release from prison as proposed by Bird and Hutchinson1, had not been investigated. Prison-
based randomized trials must address either a concern that applies specifically to prisoners (as here) 
- to counter the challenge that the same trial could equally well have been conducted in the outside 
community; or be able to point to parallel trials on the outside to answer the challenge of exploiting 
prisoners’ captivity.   
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One recent international review of non-randomized community initiatives on take-home naloxone, 
mainly in USA and UK, with follow-up for 3 to 6 months of their trainees, gave an estimated fatality-
rate at witnessed opioid overdose of 6% (upper 95% confidence limit: 11%), suggesting that a target 
for the annual distribution of naloxone-kits should be 9 to 20 times a nation’s annual number of 
opioid-related deaths6.  A recent comprehensive monograph7 has documented the historical 
development (from the 1990s) and spread of take-home naloxone programmes through North 
America, Europe and Australia; and considered their practical implementation, including the training 
of naloxone recipients in how to recognise and respond to an overdose. Although supported by the 
World Health Organization8, barriers remain to accessing take-home naloxone: in most European 
jurisdictions, naloxone is a prescription-only medicine; in others (see below), its addition to the 
exempt list of prescription-only medicines did little to change clinical practice, take-home naloxone 
being deemed contentious9 by some, complex10  by others. When the notification of overdose events 
triggers a report to the police, this may discourage witnesses from contacting emergency medical 
services; and the need to inject naloxone can prove a psychological barrier for some responders as 
well as being a potential health risk for all who administer the injection7.  
 
In 2005, naloxone was added to UK’s exempt list of prescription-only medicines that can be 
administered by anyone to save life in an emergency.11   Bird, Parmar and Strang then applied to the 
UK Medical Research Council (MRC) for funding to conduct a randomized effectiveness study of NOR 
for prisoners with a history of heroin use by injection.  The definitive NALoxone InVEstigation (N-
ALIVE) trial was to investigate if NOR could reduce DRDs in the first 4 weeks after release by 30% and 
in weeks 5-12 by 20%. In 2008, MRC funded the N-ALIVE pilot trial to randomize the first tenth of 
56,000 prisoners needed for the main trial: half in Scotland, the other half in 15 prisons in England 
and Wales. The rationale for the N-ALIVE trial has been previously described12. 
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In January 2011, Scotland became the first nation to make both community-based take-home 
naloxone and NOR for eligible prisoners a funded public health policy.6 13-15 Wales followed suit later 
in 2011.16 Accordingly, N-ALIVE was conducted in English prisons only, and its target accrual reduced 
to 2,800 participants. 
Our a priori estimation of the likely effectiveness of naloxone1 accounted for some-one else being 
present four-fifths of opiate overdoses12; and that, most often, the others present (peers or family-
members) were willing to intervene but lacked effective means17.  
 
We report the key feasibility outcomes of the N-ALIVE pilot trial compared with prior expectations in 
the trial protocol (ISRCTN34044390)18, as follows: 
i) Participation by prisons and prisoners; 
ii) Consents for randomization, Returned Prisoner Self-Questionnaire (RPSQ), phone-contact 
sub-study; 
iii) Receipt of RPSQs;  
iv) NOR-carriage and overdose-presence;  
v) Whether the N-ALIVE main trial could go ahead as planned, including assessment of to 
whom NOR was administered. 
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METHODS 
 
Design: plausible effectiveness and main trial size, plus key assumptions to be checked by pilot 
trial 
N-ALIVE was a randomized controlled trial of parallel groups (see Figure 1). Research-trained prison-
based N-ALIVE workers recruited and consented eligible prisoners. 
 
The N-ALIVE main trial was to investigate if NOR could reduce DRDs in the first 4 weeks after release 
by 30%, from 140 to 98 per 28,000 eligible releases; and in weeks 5-12 by 20%, from 35 to 28 per 
28,000 eligible releases, for which randomization of 56,000 eligible releases would be needed for 
80% power at 5% significance level. In 2008, MRC funded the N-ALIVE pilot trial to randomize the 
first tenth of 56,000 prisoners needed for the main trial: half in Scotland, the other half in prisons in 
England and Wales. 
 
Our a priori estimation of NOR’s likely effectiveness in the main trial took into account that: a) some-
one else is present at 80% of opiate overdoses12; b) 75% of ex-prisoners randomized to NOR would 
carry NOR in the first 4-weeks, reducing to 50% in weeks 5-12, but negligible thereafter18; c) most 
often, the others present (peers or family-members) are willing to intervene17 but, conservatively, 
we assumed a 50:50 chance that present others would have the presence of mind to locate, 
assemble and administer NOR to the ex-prisoner18. Hence, NOR’s plausible effectiveness at reducing 
DRDs was 80%*75%*50%, or 30%, in the 1st 4-weeks, but reduced to 20% in weeks 5-12. 
 
In Scotland and in England and Wales, the N-ALIVE pilot trial was to test our key assumptions on i) 
participation, ii) consents, iii) receipt of RPSQs, iv) NOR-carriage and overdose presence, and hence 
v) whether the N-ALIVE main trial could go ahead as planned, including by assessment of to whom 
NOR was administered. 
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Because the N-ALIVE pilot trial could randomize in English prisons only, its target accrual reduced to 
2,800 participants, sufficient for assessing i) to v) for England. Key outcome measures and prior 
expectations for the pilot trial18 are detailed in Table 1.  The N-ALIVE pilot trial was approved by 
Essex 2 Research Ethics Committee. 
 
Data Collection 
Study forms were sent by our prison-based N-ALIVE workers to MRC Clinical Trials Unit by post or 
fax.  Reporting of release-date was particularly important as marking the start of a participant’s at-
risk period.  Screening logs for eligibility were introduced in September 2012.   
 
The randomization form checked a potential participant’s eligibility and consents and provided the 
information needed for minimization (see below). Other forms recorded the participant’s release-
date or date of prison-transfer. Information on date and cause of death within 4, 12 weeks and six 
months of a participant’s N-ALIVE release-date was obtained from the Office for National Statistics 
by checking periodically against registered deaths, most recently on 21 April 2016. The RPSQ was 
designed to answer objectives iv) and v).  
 
Eligibility, Randomization and Consent 
Eligibility criteria were age greater than 18 years (upper limit of 44 removed 16 months into the trial 
because 10% of otherwise eligible prisoners were being excluded, see Table 2), history of heroin use 
by injection, incarcerated for at least 7 days, expected release date within 3 months of 
randomization-date, not previously randomized in N-ALIVE trial and then consent withdrawn prior to 
release, and written informed consent.  Exclusion criteria were known history of anaphylactic 
reaction to naloxone, confirmed/declared pregnancy or pregnancy intended within six months, 
normally resident outside of UK, and randomization-date within six months of most recent N-ALIVE 
release-date (or, if missing, within one year of previous randomization-date).  
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Participants were randomized (1:1) by MRC Clinical Trials Unit to receive on release a pack 
containing either a single ‘rescue’ injection of naloxone or a control pack which did not contain 
naloxone – there was no placebo. Minimization (with 80:20 randomization) was applied across: 
gender, age-group (18-24, 25-34, 35+ years), re-randomization, management of opioid dependency 
at randomization (substitution, detoxification, other), and likely interval from randomization to index 
release (within 28 days, 4-12 weeks).  
 
Consent for mortality follow-up was mandatory at the time of consent for randomization, but could 
be withdrawn while participants were still in prison: in such a case, the participant would be 
withdrawn from the trial and no attempt would be made to provide a pack on release. Additionally, 
prisoners were asked for their consent for i) record-linkage to establish if participants had had any 
admissions to accident and emergency departments for non-fatal overdose in the 12 weeks 
following their N-ALIVE release-date; and ii) randomization in a once-only phone-contact sub-
study18, see Figure 1 and  Supplementary.  
 
The trial was double-blind prior to release so that, while the participant was still in custody and pre-
release, neither the participant nor prison-based N-ALIVE staff nor prison staff knew the allocation.  
Participants learned their allocation when they opened the pack at the time of their release.   
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N-ALIVE packs  
Each prison had a supply of pre-numbered sealed N-ALIVE packs19. Control and naloxone packs were 
identical in appearance, sounded alike when shaken, and were similar weights. All packs contained 
the N-ALIVE DVD, a wallet and had tamper-evident stickers attached. 
 
The wallet in the control pack did not contain a syringe. The wallet in the naloxone pack included all 
the same material as the control wallet but also contained a pre-filled syringe, the unscrewed 
plunger rod for the syringe and a safety-covered, sterile-packed hypodermic needle, see 
Supplementary. The plunger had been removed from the syringe barrel so that both fitted into the 
N-ALIVE wallet; both had to be fitted to the syringe before use. The syringe contained 2mg of 
naloxone hydrochloride in 2ml of solution, for once-only intramuscular injection in the event of 
overdose.  During information and consent sessions, participants were advised on how to administer 
the N-ALIVE-recommended 0.8mg intramuscular dose of naloxone.  For trial purposes, the naloxone 
needed to be a single product19. As none of the available products fitted our needs well, the correct 
dose in single product form was most crucial. Accordingly, we selected the 2mg pre-loaded syringe 
as an acceptable formulation for the pilot trial period19; which necessitated additional instructions 
for administration to be limited to a 0.8mg dose.  
 
Returned Prisoner Self-Questionnaire   
We asked participants if they were willing to complete an anonymous follow-up questionnaire, if 
they returned to prison within six months of their most recent N-ALIVE release date. The RPSQ 
identified the participant’s randomized assignment and the time-interval between the preceding N-
ALIVE release-date and completion-date but, to encourage frankness, the identity of the respondent 
was not recorded.   Forms were neither checked nor overseen by the N-ALIVE worker unless the 
respondent so chose. 
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Statistical Analysis 
All validly randomized participants who were released from custody before 9 December 2014 are 
included in the analyses. 
 
Simple summary statistics for percentages or counts (together with 95% confidence intervals, CIs) 
are used to assess consistency with prior expectations: on consents, RPSQs, NOR-carriage in the 1st 
4-weeks, overdose presence and the use made of NOR to save the life of others than those for 
whom it was prescribed. Comparison of rates between NOR versus control group, based on RPSQs, is 
by chi-squared or Fisher’s exact test, as appropriate. 
 
Formal comparison of risk-behaviours versus perception between NOR versus control is based on a 
composite score for risk-behaviours, derived post-hoc from RPSQs. Early cessation of randomization 
in the N-ALIVE pilot trial made it unlikely that subsequent NOR-evaluations would be individually 
randomized. We therefore needed to make best use of the N-ALIVE pilot trial’s data to explore 
whether those randomized to NOR had increased the riskiness of their heroin use soon after release, 
as distinct from how participants perceived that their behaviour had been changed by taking part in 
N-ALIVE. 
 
Risk Score 
To analyse how provision of NOR impacted on participants’ heroin use and related risk behaviours 
soon after release, a risk score based on RPSQ responses was devised by SMB and AMM; and agreed 
by JS and MKBP (see Supplementary for how individual questions were scored) before being 
implemented by LC and tested for interaction (NOR versus control) against perceived behaviour-
change. 
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RESULTS 
Recruitment: prisons and participants 
The trial was conducted in 16 prisons in England. Based on screening logs, the consent-rate for 
randomization among eligible prisoners was 72% (1283/1777, 95% CI: 70% to 74%), just short of our 
prior assumption of 75% (Table 1).   
 
Between May 28th 2012 and December 8th 2014, we randomized 1685 participants (842 to NOR; 843 
to control).  Nine participants are considered ‘not-randomized’ because they were withdrawn prior 
to release: four withdrew consent for mortality follow-up prior to their release, while five were 
found to be ineligible, see Figure 2 [CONSORT].   
Consent to complete the RPSQ was given by 85% of participants (1417/1676), better than our prior 
expectation of 75%.  Consent to take part in the phone-contact study was provided by 56% 
(946/1676, 95% CI: 54% to 59%) of participants, better than our prior assumption of 50%.   
 
Re-Randomizations  
Of the 129 participants randomized more than once, 61 had received naloxone on the first occasion 
while 68 received control, consistent with expectation (64.5 each) if prior allocation did not 
influence the decision to be re-randomized. 
 
Early cessation of randomization: decisions by Trial Steering-Data Monitoring Committee (TS-
DMC) 
We closed the trial to accrual on 8th December 2014, ahead of our planned closure date20. An 
unscheduled interim analysis of the feasibility outcomes of the N-ALIVE pilot trial was prompted by 
the release on 28th October 2014 of the 3rd year of results from Scotland’s National Naloxone 
Programme21, see Figure 3.  
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When randomization to N-ALIVE stopped, all participants who remained in custody were to be 
offered naloxone on their release, including those due to receive a control pack.   The Principal 
Investigators at our prisons so agreed.  Participants were otherwise followed up per-protocol.   
 
Baseline Characteristics 
The baseline characteristics and treatment allocation of the 1557 randomized participants who were 
released by 8th December 2014 (93% of the 1676 who were eligible to receive a pack on release) are 
shown in Table 2.  
 
Provision of Packs on Release 
Of those participants released before 8th December 2014, 81% received their N-ALIVE pack on 
release (1266/1557; 95% CI: 79% to 83%).   
 
RPSQs: Return-rate and Findings 
We received 218/1557 (14%) RPSQs by December 8th, 2014; 205 with information on treatment 
assignment (112 naloxone; 93 controls), consistent with our prior expectation of 207 (95% CI:  179 to 
235), see Table 1. Median and mean time (sd) from release-date to RPSQ-completion were 64 and 
80 (62) days.  
 
(a) naloxone carriage and administration: Of RPSQ-respondents assigned to NOR, 76% (85/112; 95% 
CI: 68% to 84%) told a family member or friend about their naloxone (Table 3) and 71% (80/112; 
95% CI: 63% to 79%) reported carriage of naloxone in the first 2-weeks post-release, consistent with 
prior expectation (Table 1). Naloxone acquisition from other sources occurred at a non-differential, 
low rate (12/205, 95% CI; 2.6% to 9.1%). More often, RPSQ-respondents reported that their NOR had 
been administered to ‘save’ someone else (14%; 16/112) than themselves (5%; 5/112), see also 
Figure 3.  
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Twenty-one percent (23/112) reported administration of naloxone to themselves or another before 
the arrival of a doctor or ambulance versus 9% (8/93) for controls (chi-square on 1df = 5.64; p=0.02). 
Cumulative accounting for overdose victims being taken to hospital was 26% (29/112) for NOR 
versus 28% (26/93) for controls; chi-square on 1df = 0.11 (p=0.74).  
 
(b) personal drug use, injecting and overdose events: Two-thirds of RPSQ-respondents had used 
heroin in the first fortnight post-release (67%, 137/205).  
 
Half (105/205) of the RPSQ-respondents had injected in the first fortnight – 58% (65/112) for NOR 
and 43% (40/93) of controls; 26% (53/205; 95% CI: 20% to 32%) had injected when alone in the first 
2-weeks post-release, on a mean of six days out of 14 (95% CI: 4.9 to 7.1 days), broadly consistent 
with our prior expectation of someone else present at 80% of opiate overdoses (Table 3; Table 1).  
 
Five percent of RPSQ-respondents (10/205) had personally experienced an overdose within the first 
fortnight – 7% (8/112) for NOR and 2% (2/93) of controls (Fisher’s exact test, p=0.12). Thereafter 
until re-imprisonment, the proportion personally overdosing was 5% (11/205) for NOR and controls 
alike. 
  
(c) witnessed overdoses and actions taken: Fifteen percent of RPSQ-respondents (31/205) had 
personally witnessed an overdose in the first fortnight post-release – 17% (19/112) for NOR and 13% 
(12/93) of controls. Thereafter until re-imprisonment, the witness-proportion was 15% (30/205) for 
NOR and controls alike.  
 
(d) opinions about NOR and the N-ALIVE trial: Taking part in N-ALIVE was positively associated with 
safer heroin use by 60/112 (54%) RPSQ-respondents randomized to NOR and 30/93 (32%) of 
controls (chi-square on 1df = 9.37, p<0.002). Suggestions made by 113 RPSQ-respondents were most 
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commonly:  ‘everyone should get naloxone’ (22), ‘everyone should get naloxone not just 50:50’ (10); 
‘availability and access’ (11); ‘safer perception’ (8), ‘education and awareness’ (8); and ‘research trial 
a good idea’ (6), see Supplementary.  Fifty difficulties were cited, the top three being: ‘didn’t get 
naloxone’ (12), ‘no pack on release’ (7) and ‘police not aware’ (6).   
 
Four difficulties were potential adverse events: (1) because police were unaware of the N-ALIVE pilot 
trial, one ex-prisoner would have been arrested but for intercession by a drug-intervention-
programme worker; (2) ex-prisoner’s partner was worried about children finding his naloxone; (3) 
acquaintance of another ex-prisoner took the naloxone “to see if he got a buzz from it”; and (4) ex-
prisoner was unsure how much of naloxone to administer to a person who had overdosed.  
 
Risk Score 
Table 4 shows that RPSQ-respondents’ mean risk score was not significantly different between NOR 
(3.9) and controls (3.5).  We observed an interaction (p=0.049) between randomized assignment, 
self-reported safer behaviour and mean risk score: for controls, but not for NOR, RPSQ-respondents’ 
mean risk score was significantly lower for those who self-reported safer behaviour (2.4) versus not 
(4.0). 
Drug-Related Deaths 
Only half of the DRDs registered in England and Wales in a specific calendar year actually occur in 
that calendar year22 23 and so it was necessary to wait at least a year to report on DRDs.   
 
Nine deaths had occurred in the 12 weeks post-release among 1557 randomized participants and 
were registered with the Office for National Statistics before 21 April 2016 (Table 1 and 
Supplementary). Five were DRDs, consistent with our null-expectation of 9.7 DRDs in 12-weeks after 
release; but only two DRDs occurred in the 1st 4-weeks, well below our null-expectation of 7.9 (Table 
1).  
  
This article is protected by copyright. All rights reserved. 
 
Of the four opioid-related DRDs, three were randomized to NOR of whom one was released without 
his pack.  The participant whose DRD was not opioid-related was also randomized to NOR and had 
been released without his pack.  
 
DISCUSSION 
The N-ALIVE pilot trial has randomized more prisoners than any other prison-based, individually 
randomized controlled trial in Europe. We have shown that large-scale trials of public health 
interventions are feasible within prisons.  Prisoners themselves showed enthusiasm for the N-ALIVE 
trial - their consent rate was excellent (72%).   
 
The N-ALIVE pilot trial stopped early because its own data together with those from Scotland’s 
National Naloxone Programme were persuasive that approximately two-thirds of NOR 
administrations were not to the ex-prisoner for whom NOR was assigned.  We had no means of 
knowing the identities of these other persons: confounding of N-ALIVE’s control group could have 
occurred.  The N-ALIVE pilot trial ceased because individualized randomization to NOR cannot offer a 
clear-cut answer: other trial designs are required. 
  
We were concerned that a 50% consent-rate combined with 50% contact-rate for the half 
randomized to actual phone-contact would mean that only 195 phone-interviews would be likely to 
be achieved from 1557 randomized participants. In practice, the achievement was lower still with 81 
successful phone interviews. By contrast, RPSQs which were specifically designed to protect the 
respondent’s confidentiality achieved their anticipated response-rate. 
 
Other prior assumptions were vindicated by the feasibility trial. Few actual or potential adverse 
events were reported: one reply-card informed us that naloxone had been administered to an 
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overdose victim who had survived but had experienced withdrawal symptoms; one ex-prisoner had 
faced arrest because the police were not sufficiently aware of the N-ALIVE trial; and two 
respondents cited their or a partner’s concern for safer packaging lest children might access the 
naloxone.   
 
Notwithstanding RPSQ-respondents’ eight reports of overdose in the first fortnight for NOR versus  
two for controls, and comparable injection rates in the first fortnight post-release (Table 3), RPSQ-
respondents randomized to NOR self-reported safer heroin use compared with controls. However, 
our risk score comparisons (Table 4) showed a significant interaction whereby only for controls did 
the mean risk score align with self-reported safer behaviour.  Returned prisoners randomized to 
NOR perceived greater safety than their RPSQ answers demonstrated, which suggests some risk 
compensation about which Strang et al24 forewarned, see also other prevention policies from seat-
belt legislation to safety helmets 25-27, where a degree of risk compensation detracted in a small way 
from the policy’s overall benefit. N-ALIVE participants’ main suggestion was that naloxone should be 
made more widely available to all those at-risk.  
To our knowledge, no previous contemporaneous before/after policy-evaluation and randomized 
trial of effectiveness has had the same primary outcome: here, DRDs or opioid-related DRDs with a 
4-week antecedent of prison-release6 9 14. The N-ALIVE team convened its TS-DMC ahead of the 
release of the third year results from Scotland’s National Naloxone Programme.6 21 Consistency 
between RPSQ-responses on the administration of NOR (another vs self, 15:5) and Scotland’s data 
on the utilization of NOR by those who applied for re-supply (21:12) convinced the TS-DMC that an 
individually-randomized main trial was infeasible because only one-third of NOR administrations was 
to the ex-prisoner, two-thirds to another person whose identity was unknown to the N-ALIVE trial.  
 
No reliable inference about NOR’s effectiveness for reducing DRDs in the 12 weeks post-release can 
be drawn from the early-cessation N-ALIVE pilot Trial: five registered DRDs (four randomized to NOR, 
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of whom two were released without their pack) were fewer than our a priori null-expectation (9.7), 
perhaps because the expectation was too high rather than as a reflection of NOR’s effectiveness. 
However, the 15% fatality-rate (95% CI: 6% to 24%) at overdoses which our RPSQ-respondents 
witnessed, typically within 12 weeks of their N-ALIVE release-date, suggests that our ex-prisoners 
were present at higher-fatality-risk overdoses than suggested by an evidence-synthesis which gave a 
6% fatality-rate (95% CI: 2% to 11%) at witnessed opioid overdoses6. Explanations for the higher 
fatality-rate reported by our recidivists range from chance through assortative mixing of ex-prisoners 
– who then share the same high DRD-rate post-release - to ex-prisoners’ high DRD-risk being due to 
a higher fatality-rate per overdose (rather than to higher overdose-rate with common fatality-rate 
per overdose).  
 
The Scottish results,14 15 data on cost-effectiveness of naloxone,14 28 World Health Organization 
recommendations on naloxone,8 UK’s legal change on provision of naloxone29, England’s increase in 
opioid-related DRDs30, and prisoners’ support for initiatives like the N-ALIVE pilot trial make it timely 
for England and others to introduce a funded national naloxone policy; but also to evaluate, as 
Scotland did. In summer 2016, the National Institute for Health Research issued an evaluation-call 
for naloxone studies in England. This call could address alternative, licensed non-injectable 
formulations of naloxone or divert attention from England’s failure to fund a naloxone policy: NOR 
with, or without, take-home naloxone.  
 
Our findings add trial-based evidence to the growing consensus15 29 that pre-provision of take-home 
emergency naloxone can enable life-saving interim measures to prevent overdose deaths, and that 
the period after prison-release is not only a time of great concentration of such deaths but also of 
opportunity to prevent this major contribution to the global burden of disease31. [3882 words] 
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Research in context 
 
Evidence before this study 
The N-ALIVE pilot trial was the first randomized controlled trial to investigate provision of naloxone-
on-release (NOR) to prisoners who have previously injected heroin.  The MRC funded the N-ALIVE 
pilot trial to investigate the feasibility of a fully-powered randomized trial.  
 
Added value of this study 
The N-ALIVE pilot trial has shown that it is feasible to conduct a large prison-based randomized 
controlled trial, with good participation from both prisons and prisoners.  The finding that two-thirds 
of administrations of NOR were to someone unknown to the N-ALIVE pilot trial means that 
alternative research designs should be considered for preventative interventions against fatal 
overdose.    
 
Implications of all the available evidence 
The N-ALIVE pilot trial has demonstrated the feasibility of recruiting many prisons, and consenting 
large numbers of prisoners, to take part in randomized evaluations that matter to prisoners. The 
practicality of NOR has now been demonstrated in two prison systems (by Scotland’s National 
Naloxone Policy and by the N-ALIVE pilot trial) and so prisons, internationally, can deliver NOR.  
 
Scotland’s non-randomized before/after policy evaluation demonstrated the effectiveness of NOR 
and community-based take-home naloxone (jointly) for reducing opioid-related deaths in the 4-
weeks after prison-release.  Two-thirds of administrations of NOR (Scotland; N-ALIVE) were to some-
one other than the ex-prisoner for whom NOR was prescribed. The N-ALIVE pilot trial reacted 
promptly to external data from Scotland and from the trial itself to close the N-ALIVE trial to 
recruitment.  
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Between 6 000 and 8 000 drug-induced deaths are reported in Europe every year, with opioids their 
major cause. The European Monitoring Centre for Drugs and Drug Addiction exhorts member-states 
that many of these deaths could be prevented by adequate peer intervention using naloxone. Age-
related rising numbers of opioid-related DRDs complicate before-after evaluations, as in Scotland. 
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Table 1: Feasibility outcomes: summary of prior assumptions and actual findings 
 
Outcome Prior Assumption Actual Comment 
Number of 
Participating 
Prisons 
11 prisons in Scotland 
14 prisons in England 
16 prisons in England (15 
open, 1 closed to recruitment) 
Consistent 
with 
expectation 
Target 
Participant 
Accrual 
 
5600 participants  
Original sample size requirement 
was up to 10% of 56,000 
participants 
Target revised down to 2,800 
for England due to non-
participation of prisons in 
Scotland and Wales. 
Feb 2014:  Interim target 
revised to 1500 by Aug 31, 
2014 
Actual accrual at 31/8/14 was 
1392 participants. 
1500 participants achieved on 
8/10/14. 
 
Final accrual at Dec 8th, 2014: 
1685 participants  
Early 
cessation, 
see  Figure 3 
Consent for 
randomization 
by eligible 
prisoners 
75% Based on screening logs, the 
consent-rate for 
randomization among eligible 
prisoners was 72% 
(1283/1777); 95% CI: 70% to 
Upper 95% 
confidence 
limit is just 
short of our 
prior 
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74%. expectation 
Consent to 
Returned 
Prisoner Self 
Questionnaire  
(RPSQ) 
prior expectation of 75% 
 
Consent to complete the RPSQ 
was given by 85% of 
participants (1417/1676);    
95% CI: 83% to 86%. 
Above 
expectation 
Consent to 
secondary 
randomization 
in the  
phone-contact 
ancillary study 
prior assumption of 50%   
 
Consent to take part in the 
phone-contact study was 
provided by 56% (946/1676); 
95% CI: 54% to 59%. 
Above 
expectation 
Number of 
Returned 
Prisoner Self-
Questionnaires 
(RPSQs) 
333 recidivist self-questionnaires 
expected from 2500 randomized 
& released participants and so 
we expected 
333/2500x1557=207 RPSQs 
218 received from 1557 
randomized and released 
participants 
Consistent 
with 
expectation 
Carriage rate in 
1st 4 weeks 
after release 
75%  RPSQ 71% (80/112),   
95% CI: 63% to 79% 
  
Consistent 
with 
expectation 
Someone else 
present at 
overdose 
80% 
 
 
Based on RPSQs: 53/205 (26%; 
95% CI: 20% to 32%) of 
recidivists reported having 
injected when alone, and had 
done so on a mean of 6/14 
days. Hence, 95% CI for 
Consistent 
with 
expectation 
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someone else present is: 68% 
to 80%. 
 
Telephone questionnaire: 
Heroin use in the past three 
days was reported by 31/81 
(38%) of telephone contacts, 
10 of whom had injected when 
alone (12%; 95% CI: 5% to 
20%). If the past 3-day rate is 
taken as representative of the 
rate throughout the first 4-
weeks, then 95% CI for some-
one else being present at 
injector’s overdose is 80% to 
95%. 
 
Both consistent with our prior 
expectation that some-one 
else is present at 80% of opiate 
overdoses.  
Pooled estimate (based on 
weights 61% and 39%) is 79%;          
95% CI: 75% to 84%. 
Telephone 
Questionnaire 
Phone contacts 
Based on the (Probability of 
consent) x (Probability of being 
randomized to Phone Contact 
81 out of 1557 randomized 
and released participants. 
 
Well below 
expectation 
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in the 1st or 
2nd fortnight 
given consent) x (Probability of 
contact given randomized to 
Phone Contact) = 
1/8 x Number randomized & 
released (1557) = 195. 
Poisson 95% CI:  63 to 99 
Drug-related 
Deaths in 1st 4 
weeks and next 
8 weeks after 
release 
We expect 1/200*1557=7.9 or 8 
DRDs in 1st 4-weeks after release 
if NOR is not effective; and a 
further 1/800 x 1557=1.9 or 2 
DRDs in the next 8 weeks. 
2 DRDs in 1st 4-weeks post-
release; a further 3 DRDs in the 
next 8 weeks were registered 
with Office for National 
Statistics by 21 April 2016. 
1st 4-weeks, 95 % CI: 0.2 to  7.2 
12-weeks,    95% CI: 1.6 to 11.7 
Below 
expectation 
for the 1st  
4-weeks. 
Non-fatal 
overdose-
related 
admissions 
within 12 
weeks of 
release 
We assume participants’ non-
fatal overdose admissions to 
Accident & Emergency within 12 
weeks of index release to be 
between two and eight times as 
many as DRDs with 2-3 times as 
many DRDs being our best 
estimate, thus we expect 20-30 
(but up to 80) non-fatal 
overdose-related Accident & 
Emergency admissions.  
Awaiting Hospital Episode 
Statistics data from Health and 
Social Care Information 
Centre. 
No 
information 
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Table 2: Baseline Characteristics for 1557 Participants Randomized and Released by 8th December, 
2014  
Characteristic NOR Control All 
Age (Mean & s.d.) years Mean 35 years 
s.d. 7 years 
Mean 35 years 
 s.d. 6 years 
Mean 35 years  
s.d. 7 years 
 N % N % N % 
Age categories (N, %) years 
18-24  
25-34 
35-44  
45+ 
 
40 
381 
290 
47 
 
5 
50 
38 
6 
 
40  
385  
302 
46 
 
5 
50 
39 
6 
 
80 
766 
592 
93 
 
5 
50 
39 
6 
Gender (N, %) 
Males   
Females  
 
762 
12 
 
98 
2 
 
771 
12 
 
98 
2 
 
1533 
24 
 
98 
2 
Treatment for Addiction (at Randomization) 
(N, %) 
Opiate substitution 
Opiate detoxification 
Other (eg Naltrexone, no current treatment) 
Not recorded 
 
 
496 
163 
114 
1 
 
 
64 
21 
15 
<1 
 
 
503 
163 
116 
1 
 
 
64 
21 
15 
<1 
 
 
999 
326 
230 
2 
 
 
64 
21 
15 
<1 
Likely Incarceration Interval (N, %) 
(Date of randomization-Expected Release 
Date at randomization) 
Within 28 days 
4-12 weeks 
>12weeks 
Unknown release date 
 
 
 
532  
171 
17 
54 
 
 
 
69 
22 
2 
7 
 
 
 
540 
175 
13 
55 
 
 
 
69 
22 
2 
7 
 
 
 
1072 
346 
30 
109 
 
 
 
69 
22 
2 
7 
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Table 3: Responses to Returned Prisoner Self Questionnaire 
Self-Questionnaire NOR Control Total 
Number of Forms Completed 112 (51%)  
 
93 (43%)  
 
205 
 
Time from previous release 
to completion of 
questionnaire (days) 
Mean 79, Sd. 59  
Median 64  
IQR 37-108 
Mean 85, Sd. 66 
Median 64  
IQR 39-119 
Mean 82, sd. 63 
Median 64  
IQR 38-108 
Told family member/friend 
about Naloxone   
Told someone about 
Naloxone 
 
76% (85/112) 
 
79% (89/112) 
 
NA 
 
NA 
 
NA 
 
NA 
Carriage rate of Naloxone  71% (80/112) NA NA 
How Often did you carry it? 
All 
Most 
Some 
No response 
 
76% (61/80) 
16% (13/80) 
6%   (5/80) 
1%   (1/80) 
 
 
NA 
 
 
NA 
What did you do with the 
Naloxone? 
Saved other 
Saved self 
Lost it 
Had it taken away/stolen 
Given it away 
Thrown it away 
Broke the syringe 
 
 
14% (16/112) 
5%   (5/112) 
13% (14/112) 
10% (11/112) 
7%   (8/112) 
2%   (2/112) 
2%   (2/112) 
NA 
 
NA 
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No answer given 48% (54/112) 
Heroin use in the first 2 
weeks after leaving prison 
(Yes or No) 
 
(Smoke/inject) 
 
 
 
 
(Inject) 
 
 
 
 
(Inject, alone) 
 
 
 
69% (77/112)  
 
66% (74/112) 
N=74, 
Mean 9/14 days, 
sd 5 days 
 
58% (65/112) 
N=65,  
Mean 9/14 days, 
 sd 5 days 
 
23% (26/112) 
N=25,  
Mean 6/14 days, 
 sd 5 days 
 
 
65% (60/93) 
 
65% (60/93) 
N=60, 
Mean 8/14 days, 
sd 5 days 
 
43% (40/93) 
N=40,  
Mean 10/14 days,  
sd 5 days 
 
29% (27/93) 
N=26 
Mean 6/14 days,  
sd 4 days 
 
 
67% (137/205) 
 
65% (134/205) 
N=134, 
Mean 9/14 days, 
sd 5 days 
 
51% (105/205) 
N=105,  
Mean 9/14 days,  
sd 5 days 
 
26% (53/205) 
N=51,  
Mean6/14 days,  
sd 4 days 
Self-overdose <=2 weeks of 
release 
Overdose* 
Someone present 
Naloxone given 
Taken to hospital 
 
 
7% (8/112) 
8/8 
3/8 
4/8 
 
 
2% (2/93) 
1/2 
2/2 
2/2 
 
 
5% (10/205) 
9/10 
5/10 
6/10 
Self-overdose >2 weeks of 
release 
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Overdose 
Someone present 
Naloxone given 
Taken to hospital 
4% (5/112) 
3/5 
3/5 
4/5 
6% (6/93) 
6/6 
3/6 
4/6 
5% (11/205) 
9/11 
6/11 
8/11 
Presence at overdose of 
others <=2 weeks of release 
Present 
Naloxone given 
Taken to hospital 
Survived 
 
 
17% (19/112) 
10/19 
12/19 
17/19 
 
 
13% (12/93) 
1/12 
8/12 
11/12 
 
 
15% (31/205) 
11/31 
20/31 
28/31 
Presence at overdose of 
others >2 weeks of release 
Present 
Naloxone given 
Taken to hospital 
Survived 
 
 
15% (17/112) 
7/17 
9/17 
13/17 
 
 
15% (13/93) 
2/13 
12/13 
11/13 
 
 
15% (30/205) 
9/30 
21/30 
24/30 
Naloxone acquisition-rate  
chi-square on 1df = 1.46 
p=0.226 
4% (5/112)  9% (8/93) 6% (13/205) 
Do you think taking part in N-ALIVE changed your own use of heroin in the first 2 weeks after 
release? 
No 
Safer Heroin Use 
Riskier Heroin Use 
38% (43/112) 
54% (60/112) 
2%   (2/112) 
65% (60/93) 
32% (30/93) 
3%   (3/93) 
50% (103/205) 
44%   (90/205) 
2%     (5/205) 
 
* Fisher’s exact test: p=0.116.  
 
  
This article is protected by copyright. All rights reserved. 
Table 4: Risk Score Comparison, based on answers to RPSQ 
Risk Score Comparison 
(lower score, less risky) 
N Median Mean sd Se(Diff) Observed Difference 
(95% CI for Difference) 
Random Assignment 
NOR 112 4.00 3.86 3.34 0.48 0.34 
Control 93 2.00 3.52 3.43 (-0.59 to 1.27) 
Safer behaviour as N-ALIVE participant? 
No change/Unsafe  115 3.00 3.87 3.54 0.47 0.38 
Safer 90 4.00 3.49 3.18 (-0.54 to 1.30) 
Safer behaviour as N-ALIVE participant? (answers by those assigned to control group) 
No change/Unsafe 63 3.00 4.03 3.50 0.71 1.60* 
Safer 30 2.00 2.43 3.07 (0.20 to 3.00)  
Safer behaviour as N-ALIVE participant?  (answers by those assigned to NOR group)  
No change/Unsafe  52 3.50 3.67 3.61 0.64 -0.35* 
Safer 60 4.00 4.02 3.12 (-1.61 to 0.91)  
Test for Interaction: Difference in differences* (Control-NOR)=1.94,  
Se  for Difference in differences* (Control-NOR) = 0.98  
Hence, 95% CI for Difference in differences* is from 0.008 to 3.876 (p=0.049) 
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 Figure 1: N-ALIVE pilot trial design and outcome measures 
A full list of the trial’s outcome measures is described in the N-ALIVE protocol, which is available on 
the N-ALIVE webpage:  http://www.ctu.mrc.ac.uk/13391/13399/18277/n-alive_trial_protocol 
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 Figure 2: CONSORT Diagram for N-ALIVE pilot Trial 
NB. Screening records have been kept only since September 2012 to provide a snapshot of the 
proportions deemed eligible and subsequently randomized. 
* Excluded from Intention-to-Treat (ITT) analysis participants released after recruitment 
closure (n=48, 40) 
** Included in Per-Protocol (PP) analysis participants released with pack only. 
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Figure 3: Explanation of the decision by N-ALIVE’s Trial Steering – Data Monitoring Committee 
(TSDMC) to cease randomization in the N-ALIVE pilot trial 
 
An unscheduled interim analysis of the feasibility outcomes of the N-ALIVE pilot trial20 was prompted 
by imminent release on 28th October 2014 of the 3rd year results from Scotland’s National Naloxone 
Programme.21  
 
This interim analysis showed that the N-ALIVE participants who received naloxone were more likely 
to use it to save another person’s life rather than use on self in a ratio of approximately 3:1 
(Another: Self (A:S), 15:5 then; 16:5 now); which was corroborated in broad terms by the Scottish 
data for NOR (A:S, 21:12).21 This dual finding had major implications for the main N-ALIVE trial, which 
was designed around individual randomization.   
 
First, mortality for the majority of those to whom naloxone was administered would not be captured 
as we were following up only the N-ALIVE participants.   
 
Second, individuals in the control group of the trial could potentially receive the naloxone, thereby 
diluting the size of any effect of naloxone in the trial context.  
 
Even if, at best, half the administrations of NOR were on self (17/53, 99% CI: 15% to 49%), the size of 
the trial (with individual randomization) needed reliably to detect the required effect-size of 20% to 
30% reduction in DRDs would be infeasibly large.   
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As the main trial could not go ahead as planned, it was not appropriate to continue randomizing 
participants to the N-ALIVE pilot trial.  This decision was unanimously agreed by the TS-DMC.  This 
decision was also approved by our appointed Essex 2 Research Ethics Committee.  
 
The finding that Scotland’s percentage of opioid-related deaths with a 4-week antecedent of prison-
release had decreased from 193/1970 (9.8%) in 2006-2010 to 76/1212 (6.3%) in 2011-2013 
(p<0.001) led the TS-DMC to advise that, when randomization to N-ALIVE stopped, all participants 
who remained in custody be offered naloxone on their release, including those who had been due to 
receive a control pack.  
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